VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLKFTFinancials

Lakefront Biotherapeutics N.V. (LKFT) Income Statement

22Y historyFree accessUpdated daily

Revenue has been highly erratic, moving from $77.9M in 2024Q2 to $6.5M in 2026Q1 before the $900.8M spike in 2025Q4, and gross margin swung between -185.8% and 99.9%, suggesting reported profitability is not yet structurally established.

Income StatementBalance SheetCash FlowRatios

LKFT Income Statement

Annual statement

LKFT Income Statement

Lakefront Biotherapeutics N.V. (LKFT) annual income statement — 22-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04
Sales/Revenue926.95M1.11B275.65M239.72M241.25M484.85M478.05M834.9M288.84M127.09M129.52M39.56M69.37M137.7M136.27M95.89M122.41M93.09M76.98M65.94M35.15M11.24M7.78M
Revenue Growth %223.07%303.5%14.99%--50.24%1.42%-42.74%189.06%127.27%-1.88%227.37%-42.97%-49.62%1.05%42.11%-21.67%31.5%20.93%16.75%87.57%212.74%44.53%-
Cost of Goods Sold43.55M29.74M34.86M031.43M1.63M523.67M420.09M322.88M218.5M139.57M129.71M111.11M41.3M48.18M124.99M116.02M85.1M27.77M30.17M19.53M4.83M1.29M
COGS % of Revenue-2.67%12.65%-13.03%0.34%109.54%50.32%111.79%171.93%107.77%327.87%160.17%29.99%35.36%130.35%94.78%91.41%36.07%45.75%55.57%42.96%16.56%
Gross Profit883.41M1.08B240.79M239.72M241.25M483.22M-45.61M414.81M-34.04M-91.42M-10.06M-90.15M-41.74M96.4M88.09M-29.1M6.39M7.99M49.21M35.77M15.62M6.41M6.49M
Gross Margin %95.3%97.33%87.35%100%100%99.66%-9.54%49.68%-11.79%-71.93%-7.76%-227.87%-60.17%70.01%64.64%-30.35%5.22%8.59%63.93%54.25%44.43%57.04%83.44%
Gross Profit Growth %-349.57%0.44%--50.07%1159.36%-111%1318.6%62.76%-808.97%88.84%-115.97%-143.3%9.43%402.73%-555.1%-19.99%-83.76%37.57%129.02%143.63%-1.2%-
Operating Expenses272.27M581.12M429.12M327.99M372.31M648.81M133.02M46.06M333.64M216.89M141.01M129.01M105.32M106.37M90.19M3.84M4.92M6.06M61.3M50.99M26.8M12.78M10.1M
OpEx % of Revenue-52.25%155.68%136.82%154.32%133.82%27.82%5.52%115.51%170.66%108.87%326.08%151.83%77.25%66.18%4%4.02%6.51%79.63%77.33%76.25%113.7%129.83%
Selling, General & Admin79.81M111.96M96.88M94.25M103.31M167.22M185.22M96.96M29.64M20.56M16.95M20.31M9.08M21.76M20.4M25.39M24.07M19.01M23.4M21.9M13.94M6.16M4.65M
SG&A % of Revenue-10.07%35.15%39.32%42.82%34.49%38.75%11.61%10.26%16.18%13.08%51.33%13.09%15.8%14.97%26.48%19.66%20.42%30.4%33.21%39.64%54.79%59.84%
Research & Development189.87M459.42M335.46M241.29M269.8M491.71M523.67M420.09M322.88M218.5M139.57M129.71M111.11M99.38M80.26M00038.73M30.63M15.86M6.7M5.44M
R&D % of Revenue-41.31%121.7%100.65%111.83%101.42%109.54%50.32%111.79%171.93%107.77%327.87%160.17%72.17%58.9%---50.31%46.46%45.13%59.61%69.99%
Other Operating Expenses-1000K9.74M-3.21M-7.56M-802K-10.11M-575.87M-470.99M-18.87M-22.17M-15.51M-14.63M-14.87M-14.77M-10.47M-21.56M-19.15M-12.95M-825K-1.54M-2.99M-78K0
Operating Income611.14M501.39M-188.34M-88.26M-131.06M-165.6M-178.63M368.75M-44.81M-89.8M-11.49M-89.44M-36.62M-11.02M-6.61M-32.94M1.03M1.66M-15.21M-21.84M-11.81M-6.65M-3.61M
Operating Margin %65.93%45.08%-68.33%-36.82%-54.32%-34.15%-37.37%44.17%-15.51%-70.66%-8.87%-226.08%-52.8%-8%-4.85%-34.35%0.84%1.78%-19.77%-33.12%-33.59%-59.16%-46.39%
Operating Income Growth %-366.22%-113.38%-20.86%7.3%-148.44%922.97%50.1%-681.5%87.15%-144.22%-232.34%-66.72%79.93%-3294.47%-37.78%110.89%30.33%-84.97%-77.55%-84.31%-
EBITDA493.53M557.27M-142.84M-44.62M-65.49M-144.29M-170.67M374.24M-39.73M-85.52M-7.31M-86.04M-31.98M-2.87M2.4M-20.84M12.67M8.61M-7.85M-13.49M-7.08M-5.33M-2.6M
EBITDA Margin %53.24%50.1%-51.82%-18.61%-27.15%-29.76%-35.7%44.82%-13.75%-67.29%-5.64%-217.48%-46.09%-2.08%1.76%-21.73%10.35%9.25%-10.2%-20.45%-20.14%-47.46%-33.5%
EBITDA Growth %245.82%490.14%-220.12%-54.61%15.46%-145.61%1042.06%53.55%-1070.02%91.51%-169.09%-1015.67%-219.47%111.51%-264.53%47.07%209.72%41.8%-90.45%-32.73%-104.8%-
D&A (Non-Cash Add-back)3.04M55.88M45.5M43.64M65.57M21.3M7.96M5.5M5.08M4.29M4.18M3.4M4.65M8.15M9.01M12.1M11.63M6.96M7.37M8.35M4.73M1.31M1M
EBIT490.49M303.09M-2.17M7.39M-61.69M-122.23M-178.63M368.75M-30.64M-114.57M-11.49M-119.58M-35.09M-15.98M-5M-33.59M2.15M2.4M-9.25M-21.72M-11.44M-6.28M-3.41M
Net Interest Income25.57M44.12M88.86M77.84M8.94M-8.73M-150.48K14.17M3.87M1.67M8.26M1.13M1.88M1.32M1.46M-793K-443K27K-3.26M-666K-687K-1K40K
Interest Income25.69M46.34M89.77M79.61M18.09M2.87M11.43M16.01M5.22M3.04M1.61M1.38M1.16M1.19M1.02M859K1.11M738K1.86M1.08M370K368K202K
Interest Expense122.27K2.22M911K1.77M9.15M11.59M11.58M1.84M780K936K47K252.83K110K157K150K1.65M1.56M711K5.13M1.75M1.06M369K162K
Other Income/Expense179.88M-200.52M185.25M93.89M60.21M48.57M-131.14M-219.89M15.6M-25.7M65.74M-30.18M1.42M780K2.87M-792K-443K26K-3.26M-666K-687K-1K40K
Pretax Income791.02M300.87M-3.08M5.63M-70.85M-123M-309.77M148.85M-29.21M-115.51M54.25M-119.63M-35.2M-11.19M-5.15M-33.73M588K1.69M-18.48M-22.51M-12.49M-6.65M-3.57M
Pretax Margin %85.34%27.05%-1.12%2.35%-29.37%-25.37%-64.8%17.83%-10.11%-90.89%41.88%-302.37%-50.75%-8.13%-3.78%-35.17%0.48%1.81%-24%-34.13%-35.54%-59.17%-45.88%
Income Tax970.38K-18.62M-1.8M9.61M572K2.42M1.23M165K50K198K235K-1.22M2.1M-3.12M569K-630K-3.78M-1.32M-3.89M-558K-1.16M-110K21K
Effective Tax Rate %0.12%-6.19%58.44%170.9%-0.81%-1.97%-0.4%0.11%-0.17%-0.17%0.43%1.02%-5.97%27.83%-11.04%1.87%-643.2%-78.58%21.07%2.48%9.28%1.65%-0.59%
Net Income796.09M320.88M74.08M211.7M-217.99M-125.42M-305.44M149.84M-29.26M-115.7M54.01M-118.41M33.21M-8.08M-5.72M-33.1M4.37M3.01M-14.58M-21.95M-11.34M-6.54M-3.59M
Net Margin %85.88%28.85%26.88%88.31%-90.36%-25.87%-63.89%17.95%-10.13%-91.04%41.7%-299.29%47.88%-5.87%-4.2%-34.52%3.57%3.23%-18.95%-33.29%-32.25%-58.19%-46.15%
Net Income Growth %282.61%333.15%-65.01%--73.81%58.94%-303.83%612.13%74.71%-314.22%145.61%-456.54%511.08%-41.22%82.71%-857.37%45.18%120.64%33.55%-93.63%-73.29%-82.25%-
Net Income (Continuing)790.05M319.49M-1.28M-3.99M-71.42M-125.42M-311M148.69M-29.26M-115.7M54.01M-118.41M-37.3M-16.81M-5.72M-33.1M4.37M3.01M-14.58M-21.95M-11.34M-6.54M-3.59M
Discontinued Operations1.46M1.39M75.36M215.69M-146.57M05.57M1.16M000070.51M8.73M000000000
Minority Interest00--0000000000000000000
EPS (Diluted)12.134.871.123.21-3.32-1.91-4.782.60-0.56-2.341.14-3.321.10-0.28-0.22-1.250.170.13-0.69-1.06-0.84-0.73-0.60
EPS Growth %279.98%334.82%-65.11%--73.82%60.04%-283.85%564.29%76.07%-305.26%134.34%-401.82%492.86%-27.27%82.4%-835.29%30.77%118.84%34.91%-26.19%-15.07%-21.67%-
EPS (Basic)-4.871.123.21-3.32-1.91-4.782.60-0.56-2.341.18-3.321.10-0.28-0.22-1.250.170.14-0.69-1.06-0.84-0.73-0.60
Diluted Shares Outstanding65.66M65.9M66.14M65.88M65.7M65.5M65.08M57.61M52.11M49.48M45.7M35.7M30.11M28.79M26.55M26.4M24.28M21.66M21.19M20.68M13.54M8.94M5.94M
Basic Shares Outstanding65.66M65.9M66.14M65.88M65.7M65.5M65.08M57.61M52.11M49.45M45.7M35.67M30.08M28.79M26.55M26.4M24.28M21.66M21.19M20.68M13.54M8.94M5.94M
Dividend Payout Ratio-----------------------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Volatile revenue and recurring operating losses

Revenue Erratic Without Clear Durable Trend

Based on reported quarterly figures, LKFT's revenue swung from $77.9M in 2024Q2 to $6.5M in 2026Q1 before a $900.8M spike in 2025Q4, indicating highly irregular top-line behavior that resists trend extrapolation.

The series does not show a stable growth trajectory; instead it alternates between low-teens-millions quarters and isolated large inflows, which suggests revenue may be driven by lumpy one-time items such as licensing or milestone receipts rather than recurring commercial sales. The 2025Q4 figure is roughly an order of magnitude above any other quarter and appears non-recurring based on the reported data, so reported growth rates in that period should not be read as organic momentum. Investors should monitor whether revenue normalizes toward the sub-$15M run-rate seen in 2026 and warrants further investigation into the revenue composition.

Gross Margin Hinges on Lumpy Revenue

Gross margin in LKFT's reported figures ranged from -185.8% in 2026Q2 to 99.9% in 2025Q4, a dispersion that, based on reported figures, reflects cost of revenue that does not scale with the revenue line.

Negative gross margins in several quarters, such as 2024Q2 through 2024Q4 and 2026Q2, indicate that cost of sales has at times exceeded revenue, which may point to manufacturing or fixed-cost absorption issues common to biologics production. The near-100% margin in 2025Q4 appears to reflect a revenue item carrying almost no associated cost, which is not representative of ongoing economics. Peer gross margins of roughly 84% to 98% highlight that LKFT's underlying margin structure has not demonstrated the consistency seen across the comparison group.

Operating Losses Persist Against R&D Burden

As reported in the filings, R&D expense of $25.9M against $7.5M revenue in 2026Q3 produced an operating loss of $40.5M, showing that research spending continues to overwhelm the revenue base.

Operating income has been negative in most quarters outside 2025Q4, and the magnitude of losses does not appear to narrow in proportion to revenue, suggesting limited operating leverage. SG&A and R&D together have frequently exceeded gross profit, which may indicate that the cost base is sized for a commercial scale the company has not yet reached. Until operating expenses are covered by recurring gross profit, the operating line appears structurally dependent on external funding or episodic revenue.

Net Income Dominated by Non-Operating Swings

Based on LKFT's reported figures, net income moved from a $782.1M gain in 2025Q4 to a $202.1M loss in 2025Q3, a divergence from operating results that suggests non-operating items drive reported earnings.

The gap between operating income and net income in several quarters, including the 2025Q4 period where operating income of $758.8M approximates net income, implies that a large share of reported profit is not tied to core operations. Net income in 2026Q1 was positive at $14.5M despite an operating loss of $63.7M, which may reflect non-operating gains, tax effects, or other items not disclosed in the supplied data. These patterns warrant further investigation before reported EPS is treated as a reliable measure of underlying earnings power.

Narrative Rests on Unsustainable Revenue Spike

The strongest challenge to LKFT's reported results is that the $900.8M revenue in 2025Q4 accounts for the bulk of positive earnings, and per the figures, the surrounding quarters show operating losses without that item.

If the 2025Q4 inflow is non-recurring, the trailing profitability picture collapses back toward persistent operating losses seen in 2025Q1 through 2026Q3, and investors may be overestimating the company's earnings base. Short-side analysis would likely focus on the absence of consistent gross profit, recurring R&D intensity relative to revenue, and the sharp EPS reversals between adjacent quarters. Based on the reported data, the burden of proof rests on demonstrating that a repeatable commercial revenue stream exists beyond episodic receipts.

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

What was Lakefront Biotherapeutics N.V.'s (LKFT) revenue in 2025?

For fiscal year 2025, Lakefront Biotherapeutics N.V. (LKFT) reported total revenue of $1.11B. This represents a 14201.8% increase compared to $7.8M in 2004.

Is Lakefront Biotherapeutics N.V. (LKFT) profitable?

Lakefront Biotherapeutics N.V. (LKFT) is profitable, generating $320.9M in net income for the fiscal year ending 2025 with a net profit margin of 28.8%.

What is Lakefront Biotherapeutics N.V.'s operating profit margin?

Lakefront Biotherapeutics N.V. (LKFT) reported an operating income of $501.4M, resulting in an operating profit margin of 45.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Lakefront Biotherapeutics N.V.'s gross profit and gross margin?

Lakefront Biotherapeutics N.V. (LKFT) generated $1.08B in gross profit for the year, representing a gross profit margin of 97.3%. This demonstrates the company's core pricing power and production efficiency.